日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Single-Agent Divarasib in Patients With KRAS G12C-Positive Non-Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study

Divarasib 单药治疗 KRAS G12C 阳性非小细胞肺癌患者:一项 I 期研究的长期随访

Sacher, Adrian G; Miller, Wilson H Jr; Patel, Manish R; Paz-Ares, Luis; Santoro, Armando; Ahn, Myung-Ju; Dziadziuszko, Rafal; Freres, Pierre; Luo, Jia; Bowyer, Samantha; Desai, Jayesh; Markman, Ben; De Miguel, Maria; Deva, Sanjeev; Falcon, Alejandro; Alonso, Guzman; Guedes, João Daniel; Kim, Se Hyun; Krebs, Matthew G; Laurie, Scott A; Massarelli, Erminia; Medina, Laura; Prenen, Hans; Amatu, Alessio; Van Dongen, Marloes; Choi, Yoonha; Hou, Xuefeng; Qi, Ting; Lin, Mark T; Koli, Kalpesh; Mayo, Mariah C; Yau, Kenneth K; Royer-Joo, Stephanie; Chang, Julie; Jun, Tomi; Dharia, Neekesh V; Schutzman, Jennifer L; Lorusso, Patricia

A non-randomised open-label exploratory 'window of opportunity' study of TG02 treatment in patients with locally advanced primary and recurrent RAS mutant colorectal cancer

一项非随机、开放标签、探索性“机会窗口”研究,旨在评估TG02治疗局部晚期原发性和复发性RAS突变型结直肠癌患者的疗效。

Roth, Sara; Wilson, Kasmira Claire; Ramsay, Robert George; Mitchell, Catherine; Sampurno, Shienny; Pham, Toan Duc; Huei Kong, Joseph Cherng; Wong, Stephen Q; Heriot, Alexander Graham; Deva, Sanjeev; Burge, Matthew; Sverdrup, Cecilie; Moller, Anne-Sophie; Kuryk, Lukasz; Eriksen, Jon Amund; Jaderberg, Magnus; Zalcberg, John Raymond; Michael, Michael

A phase I study of the OX40 agonist BGB-A445 with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors: dose-escalation results

一项针对晚期实体瘤患者的 I 期研究,评估 OX40 激动剂 BGB-A445 联合或不联合抗 PD-1 单克隆抗体替雷利珠单抗的疗效:剂量递增结果

Desai, Jayesh; Deva, Sanjeev; Gao, Bo; Yang, Kunyu; O'Byrne, Kenneth J; Sun, Meili; Liu, Tianshu; Meniawy, Tarek; Yu, Xinmin; Voskoboynik, Mark; Davar, Diwakar; Matos, Marco; Leaw, Shiangjiin; Rahman, Tahmina; Qu, Xiaofei; Giovinazzo, Hugh; Chen, Xin; Dong, Yan; Day, Daphne

A thymine-challenge test to prospectively evaluate dihydropyrimidine dehydrogenase activity for risk of severe 5-fluorouracil-induced gastrointestinal toxicity

胸腺嘧啶激发试验用于前瞻性地评估二氢嘧啶脱氢酶活性,以预测5-氟尿嘧啶引起的严重胃肠道毒性风险

Helsby, Nuala; Sharples, Katrina; Kim, Yu Jin; Porter, David; Burns, Kathryn; Jeong, Soo Hee; Benge, Sarah; Deva, Sanjeev; Lawrence, Ben; Jackson, Christopher; North, Richard; Strother, R Matthew; Duley, John; Findlay, Michael

Blending space and time to talk about cancer in extended reality

融合空间和时间,以扩展现实的方式探讨癌症

Robb, Tamsin J; Liu, Yinan; Woodhouse, Braden; Windahl, Charlotta; Hurley, Daniel; McArthur, Grant; Fox, Stephen B; Brown, Lisa; Guilford, Parry; Minhinnick, Alice; Jackson, Christopher; Blenkiron, Cherie; Parker, Kate; Henare, Kimiora; McColl, Rose; Haux, Bianca; Young, Nick; Boyle, Veronica; Cameron, Laird; Deva, Sanjeev; Reeve, Jane; Print, Cristin G; Davis, Michael; Rieger, Uwe; Lawrence, Ben

Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma

一项评估simlukafusp alfa (FAP-IL2v)联合atezolizumab治疗复发性和/或转移性宫颈鳞状细胞癌患者的抗肿瘤活性和安全性的II期研究

Verlingue, Loic; Italiano, Antoine; Prenen, Hans; Guerra Alia, Eva Maria; Tosi, Diego; Perets, Ruth; Lugowska, Iwona; Moiseyenko, Vladimir; Gumus, Mahmut; Arslan, Cagatay; Lindsay, Colin R; Deva, Sanjeev; Taus, Álvaro; Oaknin, Ana; Rottey, Sylvie; Cicin, Irfan; Goksu, Sema Sezgin; Smolin, Alexey; Roselló-Keränen, Susana; Habigt, Christin; Marbach, Daniel; Boetsch, Christophe; Dejardin, David; Sleiman, Nassim; Evers, Stefan; Richard, Muriel; Ardeshir, Caroline; Charo, Jehad; Kraxner, Anton; Teichgräber, Volker; Keshelava, Nino; Dziadziuszko, Rafal

Oral PD-L1 inhibitor GS-4224 selectively engages PD-L1 high cells and elicits pharmacodynamic responses in patients with advanced solid tumors

口服PD-L1抑制剂GS-4224选择性地与PD-L1高表达细胞结合,并在晚期实体瘤患者中引发药效学反应。

Odegard, Jared M; Othman, Ahmed A; Lin, Kai-Wen; Wang, Adele Y; Nazareno, Jonathan; Yoon, Oh Kyu; Ling, John; Lad, Latesh; Dunbar, P Rod; Thai, Dung; Ang, Edmond; Waldron, Nicholas; Deva, Sanjeev

Intralesional SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Head and Neck Squamous Cell Carcinoma: Results from a Multicenter, Phase II Trial

在未接受过抗PD-1治疗的头颈部鳞状细胞癌患者中,病灶内注射SD-101联合帕博利珠单抗的疗效:一项多中心II期试验的结果

Cohen, Ezra E W; Nabell, Lisle; Wong, Deborah J; Day, Terry; Daniels, Gregory A; Milhem, Mohammed; Deva, Sanjeev; Jameson, Michael; Guntinas-Lichius, Orlando; Almubarak, Mohammed; Strother, Matthew; Whitman, Eric; Chisamore, Michael; Obiozor, Cynthia; Bagulho, Teresa; Gomez-Romo, Jose; Guiducci, Cristiana; Janssen, Robert; Gamelin, Erick; Algazi, Alain P

Response to BRAF-targeted Therapy Is Enhanced by Cotargeting VEGFRs or WNT/β-Catenin Signaling in BRAF-mutant Colorectal Cancer Models.

在 BRAF 突变型结直肠癌模型中,通过共同靶向 VEGFR 或 WNT/β-catenin 信号通路可增强对 BRAF 靶向治疗的反应

Tran Khanh B, Kolekar Sharada, Wang Qian, Shih Jen-Hsing, Buchanan Christina M, Deva Sanjeev, Shepherd Peter R

Population pharmacokinetics for oral paclitaxel in patients with advanced/metastatic solid tumors

晚期/转移性实体瘤患者口服紫杉醇的群体药代动力学

He, Jimmy; Jackson, Christopher G C A; Deva, Sanjeev; Hung, Tak; Clarke, Katriona; Segelov, Eva; Chao, Tsu-Yi; Dai, Ming-Shen; Yeh, Hsien-Tang; Ma, Wen Wee; Kramer, Douglas; Chan, Wing-Kai; Kwan, Rudolf; Cutler, David; Zhi, Jay